Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 72 post-ruxolitinib window

Weekly Tracker

2026-05-22 to 2026-05-28

Generated 2026-05-28 07:29 · Patient 1 — Weekly Tracker

GREEN

On Track

Metrics in normal range

AMBER

Watch

Borderline or declining

RED

Alert

Needs attention

IMPROVING

Normal

Week-over-week

DECLINING

Abnormal

Week-over-week

Doctor Summary — Week of 2026-05-22 to 2026-05-28

ATTENTION: Lowest HR is declining at 65.2 bpm (+10.6% week-over-week)
REM Sleep improved +46.8% to 1.1 h
Steps improved +33.2% to 8653 steps
Average HR declined +7.5% to 75.9 bpm -- monitor
Day 73 on ruxolitinib (started 2026-03-16)

Metric Details

HRV (RMSSD)

27.8ms

↔ -2.4%Last week: 28.4 ms

Lowest HR

65.2bpm

↑ +10.6%Last week: 59.0 bpm

Average HR

75.9bpm

↑ +7.5%Last week: 70.6 bpm

Sleep Duration

7.5h

↑ +16.6%Last week: 6.4 h

Deep Sleep

1.4h

↑ +30.3%Last week: 1.1 h

REM Sleep

1.1h

↑ +46.8%Last week: 0.8 h

Sleep Efficiency

85%

↔ +2.6%Last week: 83 %

Readiness Score

76pts

↑ +7.3%Last week: 71 pts

Recovery Index

68pts

↔ +1.8%Last week: 67 pts

Steps

8653steps

↑ +33.2%Last week: 6496 steps

Temp Deviation

0.20°C

↑ -28.3%Last week: 0.29 °C

Breath Rate

15.8brpm

↑ +7.4%Last week: 14.7 brpm

Ruxolitinib Progress

Day 73 on ruxolitinib (started 2026-03-16)

Metric	Pre-Rux Baseline	This Week	Change
HRV (RMSSD)	11.7 ms	27.8 ms	↑ +136.9%
Lowest HR	73.0 bpm	65.2 bpm	↓ -10.6%
Average HR	80.5 bpm	75.9 bpm	↓ -5.7%
Sleep Duration	6.0 h	7.5 h	↑ +25.3%
Deep Sleep	1.0 h	1.4 h	↑ +34.3%
REM Sleep	0.8 h	1.1 h	↑ +31.4%
Sleep Efficiency	79 %	85 %	↑ +7.6%
Readiness Score	69 pts	76 pts	↑ +10.4%
Recovery Index	63 pts	68 pts	↑ +8.9%
Steps	2540 steps	8653 steps	↑ +240.6%
Temp Deviation	0.21 °C	0.20 °C	↓ -0.3%
Breath Rate	14.0 brpm	15.8 brpm	↑ +12.8%

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – May 26, 2026 · Post-intervention: 72 days (ruxolitinib, March 16)